Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 18

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 18
---
 Marketing at Sprout Pharmaceuticals (acquired by Valeant), Executive Director Women’s Health at Actavis Plc, and positions
of increasing responsibility in sales and marketing at Forest Labs, Abbott Labs, and Novartis. Ms. Landon holds an MBA from Silberman
College of Business at Fairleigh Dickinson University, and a Bachelor’s degree from Kean University.

<div align='center'>9</div>

Charles Allenis one of our directors
since July 11, 2023 and since February 5, 2014 has served as the Chief Executive Officer of BTCS Inc. (“BTCS”) and the Chairman
of the Board of BTCS since September 11, 2014. Mr. Allen is responsible for BTCS’ overall corporate strategy and direction. Since
December 2, 2022, Mr. Allen has been a director of Innovation1 Biotech Inc. Since January 12, 2018, Mr. Allen has been the Chief Executive
Officer of Global Bit Ventures Inc. (“GBV”). Since October 10, 2017, Mr. Allen has been a director of GBV. Mr. Allen has extensive
experience in business strategy and structuring and executing a variety of investment banking and capital markets transactions, including
financings, initial public offerings, and mergers and acquisitions. Prior to his work in the blockchain industry at BTCS, he worked domestically
and internationally on projects in technology, media, natural resources, logistics, medical services, and financial services. He has served
as a managing director at numerous boutique investment banks focused on advising and raising capital for small and mid-size companies.
Mr. Allen received a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business Administration from
the Mason School of Business at the College of William & Mary. The Board concluded that Mr. Allen’s background and leadership
experiences in the financial industry qualify him to be a member of the Board.

Cheryl Xu is one of our directors
since July 11, 2023 and until recently served as Biogen’s Vice President, Public Policy & Government Affairs since 2020. Ms.
Xu was PhRMA’s first Representative to China. Subsequently she started a consulting business in 2005, advising well-known multinational
companies such as Pfizer, J&J and UnitedHealth Group on their market access and expansion strategies in China. Cheryl has provided
consultations to both the U.S. and Chinese governments on pharmaceutical policies including strengthening